Evidence map›Paper›PMID 25962699›Full record

SynthesisEarly intervention in psychiatry2016

Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications.

Cenk Tek, Suat Kucukgoncu, Sinan Guloksuz, Scott W Woods, Vinod H Srihari, Aniyizhai Annamalai

3 registry-linked trialsOpen access · greenAbstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Early intervention in psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 77 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 7 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02069925 nacompletednot on this map

STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.

TypeinterventionalSponsorYale UniversityRan2014 to 2020Enrolled285ConditionsPsychosis, SchizophreniaArmsEarly Detection (ED), Usual Detection
NCT05207982 phase1completednot on this mapstarted 2022, after this paper: background citation

Weight Management Program for Patients With First Episode Psychosis

TypeinterventionalSponsorState University of New York at BuffaloRan2022 to 2023Enrolled10ConditionsDiet, Healthy, Psychotic DisordersArmsFamily Based weight management program
NCT05866107 narecruitingnot on this mapstarted 2023, after this paper: background citation

Effectiveness and Feasibility of Self-Monitoring for Weight Management in Individuals With Mental Disorders Using Digital Intervention ("SWIM" Trial)

TypeinterventionalSponsorCapital Medical UniversityRan2023 to 2025Enrolled204ConditionsSchizophrenia, Bipolar Disorder, Metabolic Syndrome, Overweight and ObesityArmsEffectiveness and Feasibility of Self-Monitoring for Weight Management in Individuals with Mental Disorders Using Digital Intervention ("SWIM" trial)
3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 7 syntheses or guidelines pooled it, 171 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies.Progress in neuro-psychopharmacology & biological psychiatry · 2018
    Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. The Physical Health Care Fidelity Scale: Psychometric Properties.Administration and policy in mental health · 2020
    Trial
  13. Observational
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Trajectories of daily antipsychotic use and weight gain in people hospitalized for the first episode of psychosis.European psychiatry : the journal of the Association of European Psychiatrists · 2024
    Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Cenk TekYale University Department of Psychiatry, Connecticut Mental Health Hospital, New Haven, Connecticut, USA.
Suat KucukgoncuYale University Department of Psychiatry, Connecticut Mental Health Hospital, New Haven, Connecticut, USA.
Sinan GuloksuzYale University Department of Psychiatry, Connecticut Mental Health Hospital, New Haven, Connecticut, USA.
Scott W WoodsYale University Department of Psychiatry, Connecticut Mental Health Hospital, New Haven, Connecticut, USA.
Vinod H SrihariYale University Department of Psychiatry, Connecticut Mental Health Hospital, New Haven, Connecticut, USA.
Aniyizhai AnnamalaiYale University Department of Psychiatry, Connecticut Mental Health Hospital, New Haven, Connecticut, USA.
Connecticut Mental Health Center · USYale University · US

Funding

8/9 Predictors and Mechanisms of Conversion to PsychosisU01MH082022 · NIMH · YALE UNIVERSITY · PI WOODS, SCOTT W · 2008 to 2018
$6.0M
STEP-ED:Reducing Duration of Untreated Psychosis and its Impact in the U.S.R01MH103831 · NIMH · YALE UNIVERSITY · PI SRIHARI, VINOD H. · 2013 to 2017
$3.9M
NALTREXONE FOR ANTIPSYCHOTIC-INDUCED WEIGHT GAINR01DK093924 · NIDDK · YALE UNIVERSITY · PI TEK, CENK · 2013 to 2017
$2.3M
NIDDK NIH HHS DK093924NIDDK NIH HHS R01 DK093924NIMH NIH HHS R01 MH103831
6 · The paper itself

Abstract

aimThe first-episode psychosis (FEP) represents a critical period to prevent cardiovascular and metabolic morbidity decades later. Antipsychotic (AP)-induced weight gain is one modifiable factor in this period. The purpose of this study is to conduct a meta-analysis of AP-induced weight and body mass index (BMI) change in FEP.

methodsA comprehensive literature search identified 28 articles that reported data on AP-specific weight or BMI change in FEP. We conducted a meta-analysis of short- and long-term mean weight and BMI differences between placebo and AP medications. We also performed subgroup and meta-regression analysis to examine weight, BMI outcomes and their relationship with location (Asian vs. Western), sponsorship and baseline weight and BMIs.

resultsCompared to placebo, AP-caused mean weight gain was 3.22 kg and 1.4 points BMI in the short-term, and 5.30 kg and 1.86 points BMI in the long term. Clinically significant weight gain risk increased about twofold with AP use. Weight gain was associated with duration of AP use. AP medications were associated with more weight gain in Western samples as opposed to Asian samples. Most AP medications were associated with significant body weight gain and BMI increase in FEP patients, except for ziprasidone. Olanzapine and clozapine caused the highest weight gain compared to placebo.

conclusionExcept for ziprasidone, most AP medications were associated with body weight gain and BMI increase in FEP patients. Early and continuing effects of various AP medications on weight gain and BMI increase should be taken into consideration by clinicians.

Indexed as

Antipsychotic AgentsBody Mass IndexHumansPsychotic DisordersWeight GainAntipsychotic Agentsethnicityhaloperidolobesityschizophreniaside-effect

Identifiers

PMID25962699
PMCPMC5589463
OpenAlexW1584182128

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.